Search clinical trials for: Pembrolizumab

Total 2314 results

Amsterdam UMC, location VUmc
Maastricht University Medical Center; Erasmus Medical Center; St. Antonius Hospital

Not yet recruiting

Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) (PREOPANC-5)

Borderline Resectable Pancreatic Cancer
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Autologous Stem Cell Transplant
H. Lee Moffitt Cancer Center and Research Institute
Angiodynamics, Inc.

Recruiting

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Locally Advanced Pancreatic Cancer

United States
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Saint Petersburg State University, Russia

Recruiting

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Anaplastic Thyroid Cancer

Russian Federation
Fundacao Champalimaud

Not yet recruiting

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab (KEYPARTNER)

Triple Negative Breast Cancer | Early Breast Cancer

Portugal
Presage Biosciences
AstraZeneca

Not yet recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Not yet recruiting

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Endometrial Cancer | Recurrent Endometrial Cancer | TP53

United States
Gustave Roussy, Cancer Campus, Grand Paris
Medical University of Vienna; University Hospital, Essen; Fondazione IRCCS Istituto... and other collaborators

Recruiting

CARE1 Pragmatic Clinical Trial (CARE1)

Metastatic Kidney Carcinoma | Metastatic Kidney Cancer

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; Lantheus Medical Imaging

Not yet recruiting

PSMA Therapy and Immunotherapy in Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma
Amgen

Recruiting

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

United States
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Italy, Spain, Poland, Canada, Korea, Republic of, Hungary, Turkey, Taiwan, United Kingdom, Japan, Austria, Australia, Germany, Brazil
University of Michigan Rogel Cancer Center

Not yet recruiting

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE)

Urothelial Carcinoma

United States
Providence Health & Services
Inhibrx, Inc.

Not yet recruiting

Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

Triple Negative Breast Cancer

United States
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Not yet recruiting

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer (PRIAM)

Urologic Neoplasms | Urogenital Neoplasms | Penile Cancer | Male Urogenital Diseases | Penile Squamous Cell Carcinoma | Locally Advanced Penile Carcinoma
Filipa Lynce, MD
Merck Sharp & Dohme LLC; Zentalis Pharmaceuticals

Not yet recruiting

A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)

Breast Cancer | Triple Negative Breast Cancer | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor Negative Malignant Tumor Breast Triple

United States
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV

Georgia, India, Romania, Spain
SL VAXiGEN

Recruiting

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Korea, Republic of
Bristol-Myers Squibb

Recruiting

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Advanced Renal Cell Carcinoma (aRCC)

United States
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer
TheRas, Inc

Recruiting

Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12C

United States, Australia
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; Oncolys BioPharma Inc

Not yet recruiting

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Amgen

Recruiting

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Non-small Cell Lung Cancer | Thoracic Tumors

United States
D2M Biotherapeutics Inc.

Recruiting

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Advanced Solid Tumor

United States
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Hyogo Medical University
Merck Sharp & Dohme LLC

Not yet recruiting

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)

Malignant Pleural Mesothelioma

Japan
M.D. Anderson Cancer Center

Not yet recruiting

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Triple Negative Breast Cancer | Stage 1 cT1b-T1cN0M0

United States
Guangzhou Institute of Respiratory Disease

Recruiting

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Non-small Cell Lung Cancer Stage IIIB/IV

China
Amgen

Not yet recruiting

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan
University of Wisconsin, Madison
National Cancer Institute (NCI); National Institute of Dental and Craniofacial...

Not yet recruiting

Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)

Renal Cell Carcinoma

United States, Australia, Canada, Chile
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)

Bladder Cancer

Canada, Australia, United States, Poland, Spain
Tongji University

Recruiting

Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

Esophageal Cancer

China
Giuseppe Procopio

Not yet recruiting

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT)

Collecting Duct Carcinoma | Renal Medullary Carcinoma | Bellini Carcinoma

Italy
Inimmune Corporation
Avance Clinical Pty Ltd.

Not yet recruiting

Trial of INI-4001 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Australia
Inhibrx, Inc.

Not yet recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)
Merck Sharp & Dohme LLC
Moderna TX

Recruiting

A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Carcinoma, Squamous Cell | Skin Neoplasms

Australia, Israel
Dong-A ST Co., Ltd.

Not yet recruiting

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Bio-Thera Solutions

Not yet recruiting

A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

Carcinoma, Non-Small-Cell Lung
Jazz Pharmaceuticals

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Biliary Tract Cancer | HER2 Gene Mutation

United States, Puerto Rico
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection (PENALTY)

Progressive Multifocal Leukoencephalopathy

France
Pliant Therapeutics, Inc.

Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor

United States
GeneMedicine Co., Ltd.

Recruiting

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Malignant Melanoma

Korea, Republic of
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

Korea, Republic of, Poland, Spain
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Cervical Cancer | Cervix Cancer

United States

Search clinical trials for: Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations